Encourage Your Patients to Participate! US-Based Clinical Trials That Are Actively Recruiting in Ovarian Cancer

Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups. The Oncology Pharmacist (TOP) is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities.

This new feature in TOP aims to provide ongoing lists of US-based phase 2 or 3 clinical trials that are actively recruiting. Healthcare practitioners may use this listing in discussions with their patients to encourage enrollment. As the National Comprehensive Cancer Network has stated, “The best management of any cancer patient is in a clinical trial.”

These clinical trial listings can be found at www.ClinicalTrials.gov.

• A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer (OPAL)
  • ClinicalTrials.gov identifier: NCT03574779
  • Sponsor: Tesaro, Inc.
  • Collaborators: GSK Clinical Trials, GlaxoSmithKline

• A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
  • ClinicalTrials.gov identifier: NCT05613088
  • Sponsor: Bristol-Myers Squibb
  • Collaborator: Eisai Inc.

• A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-Resistant Ovarian Cancer Patients
  • ClinicalTrials.gov Identifier: NCT06028932
  • Sponsor: Yale University
  • Collaborator: Gilead Sciences

• T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors
  • ClinicalTrials.gov Identifier: NCT05200559
  • Sponsor: Haider Mahdi, University of Pittsburgh Medical Center, Hillman Cancer Center
  • Collaborator: Dr. Reddys Laboratories, SA

• Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
  • ClinicalTrials.gov Identifier: NCT05113368
  • Sponsor: Sarah K. Lynam, MD, Case Comprehensive Cancer Center
  • Collaborator: Bayer

• Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
  • ClinicalTrials.gov Identifier: NCT05272462
  • Sponsor: Loyola University
  • Collaborators: Cures Within Reach, Medical University of South Carolina

• Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
  • ClinicalTrials.gov Identifier: NCT04339140
  • Sponsor: Beth Israel Deaconess Medical Center
  • Collaborators: National Institutes of Health, National Cancer Institute, Dana-Farber Cancer Institute

• Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
  • ClinicalTrials.gov Identifier: NCT05983276
  • Sponsor: Loyola University
  • Collaborator: Karyopharm Therapeutics Inc

• ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
  • ClinicalTrials.gov Identifier: NCT05601752
  • Sponsor: Adaptimmune
  • Collaborator: GOG Foundation

• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
  • ClinicalTrials.gov Identifier: NCT06433219
  • Sponsor: EMD Serono Research & Development Institute, Inc.
  • Collaborator: Merck KGaA, Darmstadt, Germany

• Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
  • ClinicalTrials.gov Identifier: NCT06120972
  • Sponsor: Alexander B Olawaiye, MD
  • Collaborator: AstraZeneca

• Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
  • ClinicalTrials.gov Identifier: NCT04918186
  • Sponsor: Canadian Cancer Trials Group
  • Collaborators: Cancer Research Institute, New York City; AstraZeneca; BioAtla, Inc.

• EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
  • ClinicalTrials.gov Identifier: NCT05715216
  • Sponsor: MD Anderson Cancer Center
  • Collaborator: Mereo BioPharma

• Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
  • ClinicalTrials.gov Identifier: NCT06083844
  • Sponsor: MD Anderson Cancer Center

• Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
  • ClinicalTrials.gov Identifier: NCT05123807
  • Sponsor: MD Anderson Cancer Center

• ROCKIF Trial: Re-sensitization of Carboplatin-Resistant Ovarian Cancer With Kinase Inhibition of FAK
  • ClinicalTrials.gov Identifier: NCT03287271
  • Sponsor: Michael McHale, University of California, San Diego
  • Collaborators: Verastem, Inc.; Nine Girls Ask

• Antitumor Activity of Neoadjuvant Chemotherapy With or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer
  • ClinicalTrials.gov Identifier: NCT05145569
  • Sponsor: Haider Mahdi, University of Pittsburgh Medical Center, Hillman Cancer Center
  • Collaborator: HCW Biologics

• Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-Resistant Ovarian Cancer
  • ClinicalTrials.gov Identifier: NCT05467670
  • Sponsor: Haider Mahdi, University of Pittsburgh Medical Center, Hillman Cancer Center
  • Collaborators: ALX Oncology, Merck Sharp & Dohme LLC

• An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
  • ClinicalTrials.gov Identifier: NCT05887609
  • Sponsor: University of Colorado, Denver
  • Collaborator: ImmunoGen, Inc.